These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 16894342)

  • 21. Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration.
    Ciulla TA; Rosenfeld PJ
    Curr Opin Ophthalmol; 2009 May; 20(3):166-74. PubMed ID: 19381089
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Pharmacotherapy for pelvic endometriosis in women].
    Starczewski A; Brodowska A; Brodowski J
    Pol Merkur Lekarski; 2009 Mar; 26(153):231-3. PubMed ID: 19388539
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Angiogenesis as a therapeutic target in endometriosis.
    Djokovic D; Calhaz-Jorge C
    Acta Med Port; 2014; 27(4):489-97. PubMed ID: 25203958
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epigallocatechin-3-gallate inhibits estrogen-induced activation of endometrial cells in vitro and causes regression of endometriotic lesions in vivo.
    Laschke MW; Schwender C; Scheuer C; Vollmar B; Menger MD
    Hum Reprod; 2008 Oct; 23(10):2308-18. PubMed ID: 18603648
    [TBL] [Abstract][Full Text] [Related]  

  • 25. GnRH analogs: options for endometriosis-associated pain treatment.
    Batzer FR
    J Minim Invasive Gynecol; 2006; 13(6):539-45. PubMed ID: 17097577
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-angiogenic treatment strategies for the therapy of endometriosis.
    Laschke MW; Menger MD
    Hum Reprod Update; 2012; 18(6):682-702. PubMed ID: 22718320
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
    Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
    Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Engineered transcription factors for therapeutic angiogenesis.
    Kontos CD; Annex BH
    Curr Opin Mol Ther; 2007 Apr; 9(2):145-52. PubMed ID: 17458168
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Endometriosis in teenagers].
    Bourdel N; Matsusakï S; Roman H; Lenglet Y; Botchorischvili R; Mage G; Canis M
    Gynecol Obstet Fertil; 2006 Sep; 34(9):727-34. PubMed ID: 16950643
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular mechanisms and therapeutic development of angiogenesis inhibitors.
    Cao Y
    Adv Cancer Res; 2008; 100():113-31. PubMed ID: 18620094
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antiangiogenic effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor.
    Kong D; Okamura M; Yoshimi H; Yamori T
    Eur J Cancer; 2009 Mar; 45(5):857-65. PubMed ID: 19144509
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of cyclooxygenase-2 and vascular endothelial growth factor in ovarian endometriotic cysts and their relationship with angiogenesis.
    Ceyhan ST; Onguru O; Baser I; Gunhan O
    Fertil Steril; 2008 Oct; 90(4):988-93. PubMed ID: 18053993
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chapter 6. Mouse models to investigate anti-cancer effects of VEGF inhibitors.
    Crawford Y; Ferrara N
    Methods Enzymol; 2008; 445():125-39. PubMed ID: 19022058
    [TBL] [Abstract][Full Text] [Related]  

  • 34. VEGF inhibition: insights from preclinical and clinical studies.
    Crawford Y; Ferrara N
    Cell Tissue Res; 2009 Jan; 335(1):261-9. PubMed ID: 18766380
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic application of noncytotoxic molecular targeted therapy in gliomas: growth factor receptors and angiogenesis inhibitors.
    Idbaih A; Ducray F; Sierra Del Rio M; Hoang-Xuan K; Delattre JY
    Oncologist; 2008 Sep; 13(9):978-92. PubMed ID: 18779539
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The chick embryo chorioallantioc membrane as a model for in vivo research on anti-angiogenesis in endometriosis].
    Wang HB; Leng JH; Zhu L; Liu ZF; Sun DW; Lang JH
    Zhonghua Fu Chan Ke Za Zhi; 2007 Jan; 42(1):43-7. PubMed ID: 17331421
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.
    Shojaei F; Ferrara N
    Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Agents blocking the nuclear factor-kappaB pathway are effective inhibitors of endometriosis in an in vivo experimental model.
    González-Ramos R; Van Langendonckt A; Defrère S; Lousse JC; Mettlen M; Guillet A; Donnez J
    Gynecol Obstet Invest; 2008; 65(3):174-86. PubMed ID: 18025832
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A selective cyclooxygenase-2 inhibitor suppresses the growth of endometriosis xenografts via antiangiogenic activity in severe combined immunodeficiency mice.
    Ozawa Y; Murakami T; Tamura M; Terada Y; Yaegashi N; Okamura K
    Fertil Steril; 2006 Oct; 86(4 Suppl):1146-51. PubMed ID: 16962108
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-angiogenesis and anti-tumor effects of AdNT4-anginex.
    Dong DF; Li EX; Wang JB; Wu YY; Shi F; Guo JJ; Wu Y; Liu JP; Liu SX; Yang GX
    Cancer Lett; 2009 Nov; 285(2):218-24. PubMed ID: 19540664
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.